See more : Emami Realty Limited (EMAMIREAL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Willow Biosciences Inc. (CANSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Willow Biosciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- UpHealth, Inc. (UPH-WT) Income Statement Analysis – Financial Results
- AsiaQuest Co., Ltd. (4261.T) Income Statement Analysis – Financial Results
- Bayer Aktiengesellschaft (BAYN.DE) Income Statement Analysis – Financial Results
- R.P.P. Infra Projects Limited (RPPINFRA.NS) Income Statement Analysis – Financial Results
- Metso Outotec Oyj (MOCORP.HE) Income Statement Analysis – Financial Results
Willow Biosciences Inc. (CANSF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.willowbio.com
About Willow Biosciences Inc.
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and varin cannabinoids, such as cannabigerovarin, cannabidivarin, and tetrahydrocannabivarin. Willow Biosciences Inc. was incorporated in 1981 and is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.17M | 821.00K | 133.00K | 10.00K | 4.58K | 16.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.83M | 7.47M | 11.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -659.00K | -6.65M | -11.40M | 10.00K | 4.58K | 16.91K | 0.00 | 0.00 | 0.00 | -116.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -56.23% | -810.23% | -8,571.43% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.80M | 7.47M | 11.51M | 7.26M | 2.67M | 387.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.60M | 8.29M | 7.79M | 6.42M | 8.24M | 961.60K | 628.86K | 873.74K | 721.12K | 925.69K | 1.04M | 625.29K | 928.26K | 887.93K | 2.00M | 1.01M | 1.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 420.00K | 808.00K | 817.00K | 0.00 | 0.00 | 588.31K | 0.00 | 31.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 89.13K | 76.39K | 36.47K | 87.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29K | 7.10K |
| SG&A | 6.02M | 9.10M | 8.60M | 6.42M | 8.24M | 1.55M | 628.86K | 873.74K | 721.12K | 925.69K | 1.04M | 625.29K | 928.26K | 977.07K | 2.08M | 1.04M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 2.29K | 7.10K |
| Other Expenses | 1.54M | 0.00 | -22.00K | 0.00 | 0.00 | 0.00 | 6.61K | 30.89K | 20.08K | 60.32K | 75.13K | 50.00K | 0.00 | 3.51K | 93.90K | -84.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.35M | 19.22M | 23.31M | 16.86M | 13.08M | 1.66M | 628.86K | 873.74K | 721.12K | 925.80K | 1.04M | 626.08K | 929.43K | 979.54K | 2.08M | 1.05M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 114.44K | 202.12K |
| Cost & Expenses | 14.35M | 19.22M | 23.31M | 16.86M | 13.08M | 1.66M | 628.86K | 873.74K | 721.12K | 925.80K | 1.04M | 626.08K | 929.43K | 979.54K | 2.08M | 1.05M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 114.44K | 202.12K |
| Interest Income | 267.00K | 300.00K | 414.00K | 155.00K | 112.90K | 0.00 | 0.00 | 0.00 | 2.00 | 115.00 | 238.00 | 43.00 | 1.89K | 7.35K | 1.77K | 17.60K | 14.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.56K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 142.00K | 26.00K | 27.00K | 40.00K | 48.14K | 0.00 | 21.96K | 2.26K | 0.00 | 0.00 | 1.78K | 11.41K | 28.14K | 1.28K | 1.68K | 1.48K | 1.30K | 234.00 | 248.00 | 24.13K | 126.51K | 0.00 | 0.00 | 3.19K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.83M | 2.65M | 3.19M | 3.18M | 2.17M | 46.39K | 38.38K | 30.18K | 609.49K | 116.00 | 382.00 | 787.00 | 1.17K | 2.48K | 3.73K | 3.87K | 1.03K | 0.00 | 0.00 | 0.00 | 192.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -11.63M | -15.45M | -2.92M | -30.72M | -43.93M | -1.60M | -1.52M | -1.07M | -4.37M | -865.26K | -962.89K | -625.25K | -951.54K | -969.72K | -1.98M | -1.11M | -2.07M | -420.83K | -442.64K | -193.66K | 13.12K | -70.10K | -165.87K | -179.97K | -114.44K | -202.12K |
| EBITDA Ratio | -992.06% | -1,882.34% | -14,712.78% | -135,090.00% | -235,507.88% | -9,449.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.18M | -18.39M | -23.33M | -23.06M | -46.15M | -1.64M | -622.25K | -873.74K | -721.12K | -925.80K | -1.04M | -626.08K | -954.60K | -980.82K | -2.08M | -1.05M | -2.07M | -420.83K | -442.64K | -193.66K | -179.62K | -70.10K | -165.87K | -179.97K | -114.44K | -202.12K |
| Operating Income Ratio | -1,124.74% | -2,240.32% | -17,541.35% | -230,610.00% | -1,006,696.42% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 148.00K | 3.63M | 17.19M | -10.89M | 561.00K | 0.00 | -931.67K | -1.46M | -85.05K | 60.43K | -348.54K | -1.17M | -462.51K | -2.35M | -1.13M | -313.85K | 25.48K | -234.00 | -248.00 | 0.00 | -96.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -13.03M | -14.76M | -6.14M | -33.95M | -46.15M | -1.64M | -1.86M | -2.33M | -1.31M | -865.37K | -1.39M | -1.80M | -1.42M | -3.33M | -3.21M | -1.36M | -2.05M | -421.06K | -442.89K | 0.00 | -275.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1,112.12% | -1,797.93% | -4,616.54% | -339,460.00% | -1,006,696.42% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.00K | 53.00K | 27.00K | 40.00K | -1.58M | -114.75K | -9.81K | 2.26K | -2.00 | 60.32K | 76.90K | 11.41K | 28.14K | -118.00K | -157.00K | -211.04K | -394.90K | -16.65K | -52.54K | 217.79K | 30.14K | 70.21K | 163.31K | 183.16K | 114.44K | 202.12K |
| Net Income | -13.03M | -14.81M | -6.14M | -33.95M | -44.57M | -1.64M | -1.86M | -2.33M | -1.31M | -865.37K | -1.39M | -1.80M | -1.42M | -3.22M | -3.06M | -1.15M | -1.65M | -404.41K | -390.35K | -217.79K | -306.13K | -70.21K | -163.31K | -183.16K | -114.44K | -202.12K |
| Net Income Ratio | -1,111.69% | -1,804.38% | -4,616.54% | -339,460.00% | -972,220.55% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.10 | -0.12 | -0.05 | -0.41 | -0.62 | -0.75 | -2.58 | -8.37 | -9.72 | -10.53 | -31.15 | -128.95 | -106.73 | -267.54 | -310.63 | -177.90 | -347.50 | -118.01 | -158.36 | -126.04 | -300.12 | -59.80 | -139.10 | -156.01 | -97.47 | -17.50 |
| EPS Diluted | -0.10 | -0.12 | -0.05 | -0.41 | -0.62 | -0.75 | -2.58 | -8.37 | -9.72 | -10.53 | -31.15 | -128.95 | -106.73 | -267.54 | -310.63 | -177.90 | -347.50 | -118.01 | -158.36 | -126.04 | -300.12 | -59.80 | -139.10 | -156.01 | -96.98 | -17.50 |
| Weighted Avg Shares Out | 124.24M | 123.66M | 119.99M | 81.99M | 72.07M | 2.19M | 721.07K | 278.32K | 134.77K | 82.21K | 44.53K | 13.96K | 13.28K | 12.02K | 9.84K | 6.48K | 4.76K | 3.43K | 2.47K | 1.73K | 1.02K | 1.17K | 1.17K | 1.17K | 1.17K | 11.55K |
| Weighted Avg Shares Out (Dil) | 124.24M | 123.66M | 119.99M | 81.99M | 72.07M | 2.19M | 721.07K | 278.32K | 134.77K | 82.21K | 44.53K | 13.96K | 13.28K | 12.02K | 9.84K | 6.48K | 4.76K | 3.43K | 2.47K | 1.73K | 1.02K | 1.17K | 1.17K | 1.17K | 1.18K | 11.55K |
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Company reports record revenue of $1.7 million in Q3 Company announced a partnership in the high growth biopesticides sector that is expected to generate over $2 million in revenue in its first year Company closed a brokered financing for aggregate...
WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO
SUNNYVALE, Calif. , Nov. 7, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces that it has partnered a...
Willow Biosciences announces second collaboration with leading API manufacturer
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced a second program with a leading Active Pharmaceutical Ingredient (API) manufacturer to develop a more sustainable and cost-effective manufacturing route for a large-volume ingredient. The company highlighted that this program follows an earlier collaboration...
WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
Rapid success of first program leads to second collaboration to develop optimized enzyme for large scale manufacturing process Enzyme development expected to enable commercial-scale production of the API in 2025 SUNNYVALE, Calif. , Sept. 18, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow")...
Willow Biosciences inks commercial partnership with Kalsec
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has struck a commercial license and royalty agreement with Kalsec, a global producer of natural ingredients for the food and beverage industry. It sets out the partnership, in which Kalsec will use Willow's technology for...
WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC.
The agreement with Kalsec anticipates milestone payments for finalizing research and development work and a royalty stream for Willow upon commercialization SUNNYVALE, Calif. , Sept. 5, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on...
Willow Biosciences CEO confident in future after record revenue and new partnerships - ICYMI
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) CEO Dr Chris Savile told Proactive he is confident that Willow is on track to meet its revenue targets after the company announced record quarterly revenue of $1 million, a 660% increase compared to the...
Willow Biosciences achieves record revenue for the second quarter
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has reported higher revenue and reduced costs for the second quarter and now anticipates achieving more than $4 million in revenue for 2024 based on its existing programs. The company, which is developing biobased processes...
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Company reports record revenue of $1.0 million, an increase of approximately 600% over the second quarter of 2023 Signed strategic partnership with leading pharmaceutical manufacturer, Laurus Labs, to develop biobased processes for seven high value APIs with large, existing markets ...
Willow Biosciences lands biopesticides collaboration worth $2M in year one
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) on Wednesday announced a new funded research and development partnership with what's described as “an innovative Ag-Biotech company in the biopesticides sector.” The partnership follows the successful completion of a feasibility study, and, its expected to generate...
Source: https://incomestatements.info
Category: Stock Reports